title: Antiandrogens alone or in combination for treatment of prostate cancer: the European experience.
abstract: In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a "combination therapy" with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.
authors.affiliation: Department of Urology, University of Palermo School of Medicine, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Pavone-Macaluso
authors.forename: C
authors.initials: C
authors.lastname: Pavone
authors.forename: V
authors.initials: V
authors.lastname: Serretta
authors.forename: G
authors.initials: G
authors.lastname: Daricello
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005060:Europe; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000726:Androgen Antagonists; D005485:Flutamide